- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04918823
Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease
Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients With Ocular Surface Disease: A Pilot Study
Study Overview
Detailed Description
For this study, all subjects will receive Restasis (Cyclosporine ophthalmic emulsion 0.05%). One drop of the dispensed study drop will be instilled in the PROSE lens reservoir twice a day and the remainder of the reservoir will be filled with normal saline (0.9% sodium chloride solution). In order to standardize solutions used in the PROSE reservoir, all patients recruited will be either currently using or will be switched to buffered preservative-free normal saline (Purilens, Lifestyle Inc., pH 7.46 ) to better match the reported pH of RESTASIS (pH 6.5-8.05 ).
Outcomes will include subjective responses regarding the subject's symptoms and visual function in addition to the objective assessments of the health of the ocular surface seen on clinical examination. Results will be measured at baseline, after 1 week, and after 1 month of the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Estelle Crowley
- Phone Number: 781-726-7506
- Email: ecrowley@bostonsight.org
Study Locations
-
-
Massachusetts
-
Needham, Massachusetts, United States, 02494
- BostonSight
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written Informed Consent has been obtained prior to any study-related procedures taking place
- Subject is Male or Female, 18 years of age or older prior to the initial visit
- Is an established wearer of PROSE devices for > 6 months in both eyes
- Has a finalized PROSE lens design in both eyes, in the opinion of the clinician
- The PROSE design does NOT include fenestrations
- Subject requires PROSE devices to treat symptoms and/or signs from underlying dry eye disease, GVHD, Sjogren's syndrome, limbal stem cell deficiency, keratoconjunctivitis sicca, or ocular surface disease
- Baseline Corneal staining grade of 2 or higher in total, both eyes combined (NEI Grading System) 7
- Baseline Ocular Surface Disease Index 13 or greater
- In the opinion of the investigator, the subject can follow study instructions
- In the opinion of the investigator, the subject can complete all study procedures and visits
- Able to wear PROSE device continuously for at least 6 hours at a time without removal, in each eye
- Able to wear PROSE device for at least 10 total hours a day, in each eye
- Able to wear PROSE device in subsequent continuous sessions of 6 hours, followed by a break to re-instill Restasis in device bowl, followed by another period of continuous wear of at least 4 hours
- Currently using buffered preservative free normal saline (Purilens) in the device bowl or willing to transition to buffered preservative free normal saline (Purilens) use in the device bowl during the study
Exclusion Criteria:
- Is currently participating in any other type of eye-related clinical or research study
- Is pregnant or nursing as reported by the subject.
- Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study.
- Has had previous ocular surgery within the past 12 weeks.
- Currently uses or has a prior history of using Restasis in the last 3 months
- Currently uses or has a prior history of using Cequa in the last 3 months
- Is currently using Xiidra and has been using Xiidra for less than 3 months
- Has a history of an allergic reaction or hypersensitivity to any active or inactive ingredient found in Restasis or Cequa or Purilens.
- Is wearing a PROSE device with Tangible HydraPEG coating
- The subject is not wearing their PROSE devices daily
- The subject is only wearing a device for one eye.
- The participant is monocular
- The subject wears a PROSE lens with fenestrations
- The participant carries a diagnosis of glaucoma or ocular hypertension or glaucoma suspect AND is currently using glaucoma medications
- The participant is NOT able to wear PROSE devices for 6 hours continuously, followed by a break to re-instill Restasis, followed by an additional period of at least 4 hours of continuous wear
- Allergy to sodium fluorescein
- Allergy to lissamine green
- Allergy or intolerance to Purilens solution.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm
All subjects will receive Restasis in this study
|
Subject will use one drop of Restasis in the lens before insertion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
visual function
Time Frame: Baseline
|
subjects vision will be tested using snellen
|
Baseline
|
visual function
Time Frame: 1 week
|
subjects vision will be tested using snellen
|
1 week
|
visual function
Time Frame: 1 month
|
subjects vision will be tested using snellen
|
1 month
|
Subjects symptoms
Time Frame: baseline
|
subjects will complete questionnaires regarding device comfort and fit (Tolerability Questionnaire, scale 0 to 10, higher score means better outcome)
|
baseline
|
Subjects symptoms
Time Frame: 1 week
|
subjects will complete questionnaires regarding device comfort and fit (Tolerability Questionnaire, scale 0 to 10, higher score means better outcome)
|
1 week
|
Subjects symptoms
Time Frame: 1 month
|
subjects will complete questionnaires regarding device comfort and fit (Tolerability Questionnaire, scale 0 to 10, higher score means better outcome)
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel C Brocks, MD, Boston Sight
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Pharmaceutical Solutions
- Calcineurin Inhibitors
- Ophthalmic Solutions
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- BFS-REGEN-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Surface Disease
-
Benha UniversityCompletedOcular Surface DiseaseUnited Arab Emirates
-
Singapore National Eye CentreSingapore Eye Research InstituteSuspended
-
Mahidol UniversityUnknownOcular Surface DiseaseThailand
-
NHS LanarkshireChief Scientist Office of the Scottish Government; NHS Research ScotlandCompleted
-
Seoul National University HospitalCompletedOcular Surface Disease
-
University of Applied Sciences and Arts Northwestern...CompletedOcular Surface Disease
-
Centre Hospitalier Universitaire de Saint EtienneSociété Française des Ophtalmologistes Adaptateurs de Lentilles de ContactUnknown
-
University of California, Los AngelesNovartisRecruitingGlaucoma | Ocular Surface DiseaseUnited States
-
Glia, LLCCompletedOcular Surface DiseaseUnited States
Clinical Trials on Restasis
-
Julian M. Mackay-WigganAllerganCompleted
-
Ophthalmic Consultants of Long IslandBausch & Lomb IncorporatedCompletedKeratoconjunctivitis Sicca | Dry Eye DiseaseUnited States
-
Huons Co., Ltd.Completed
-
Huons Co., Ltd.Recruiting
-
Aurinia Pharmaceuticals Inc.Completed
-
Wills EyeAllerganCompleted
-
Taejoon Pharmaceutical Co., Ltd.CompletedDry Eye SyndromesKorea, Republic of
-
Seref istekUsak State HospitalCompleted
-
Edward Holland, MDWithdrawn
-
King Faisal Specialist Hospital & Research CenterRecruitingCarbapenem-Resistant Enterobacteriaceae InfectionSaudi Arabia